371 related articles for article (PubMed ID: 26825023)
1. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.
Doussau A; Geoerger B; Jiménez I; Paoletti X
Contemp Clin Trials; 2016 Mar; 47():217-27. PubMed ID: 26825023
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
3. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
4. Accelerated titration designs for phase I clinical trials in oncology.
Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
6. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
[TBL] [Abstract][Full Text] [Related]
7. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
8. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
9. Discrete event simulation applied to pediatric phase I oncology designs.
Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
[No Abstract] [Full Text] [Related]
10. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
Doussau A; Thiébaut R; Paoletti X
Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
[TBL] [Abstract][Full Text] [Related]
12. Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
Huang B; Bycott P; Talukder E
J Biopharm Stat; 2017; 27(1):44-55. PubMed ID: 26882496
[TBL] [Abstract][Full Text] [Related]
13. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
14. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Rossoni C; Bardet A; Geoerger B; Paoletti X
Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
[TBL] [Abstract][Full Text] [Related]
15. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
16. Dose finding with longitudinal data: simpler models, richer outcomes.
Paoletti X; Doussau A; Ezzalfani M; Rizzo E; Thiébaut R
Stat Med; 2015 Sep; 34(22):2983-98. PubMed ID: 26109523
[TBL] [Abstract][Full Text] [Related]
17. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
Lee DP; Skolnik JM; Adamson PC
J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
[TBL] [Abstract][Full Text] [Related]
18. New adaptive method for phase I trials in oncology.
Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
[TBL] [Abstract][Full Text] [Related]
19. Practical designs for Phase I combination studies in oncology.
Wages NA; Ivanova A; Marchenko O
J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
[TBL] [Abstract][Full Text] [Related]
20. [A combination phase I/II study--dose escalation plan].
Yamamoto N
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
